Celltrion: 52-week Stekima results show long-term treatment competitiveness
Celltrion said Thursday that 52-week results from a global Phase 3 trial of its autoimmune disease treatment Stekima (ustekinumab) were published in the international dermatology journal Dermatologic Therapy.
The study analyzed 52-week long-term data from a global Phase 3 trial involving 509 patients with moderate to severe plaque psoriasis. It assessed Stekima versus the originator drug across efficacy, safety, immunogenicity and pharmacokinetics.
Patients were initially assigned to Stekima or the originator. From week 16, those on the originator were randomized either to continue the originator or to switch to Stekima and were followed through week 52.
Results showed similar efficacy between the Stekima and originator groups. Among patients who switched from the originator to Stekima, efficacy remained stable compared with those who stayed on the originator. Safety findings were also comparable, with no meaningful differences in adverse events across groups.
Yuhan named a 2025 top disclosure company
Yuhan Corp. said Thursday it was selected as an “excellent disclosure company” on the Korea Exchange’s main board at the 2025 securities market disclosure awards ceremony held Wednesday at the exchange’s Seoul office in Yeouido.
The designation is awarded to listed companies based on the accuracy, timeliness and completeness of disclosures, as well as efforts to communicate with investors. Yuhan said it was recognized for strengthening trust in capital markets through faithful and transparent disclosures and for providing useful information to investors in a timely manner.
The company said it has continued to manage disclosure quality and strengthen internal processes to improve reliability while maintaining communication with investors, efforts it said contributed to greater market transparency.
The designation is awarded to listed companies based on the accuracy, timeliness and completeness of disclosures, as well as efforts to communicate with investors. Yuhan said it was recognized for strengthening trust in capital markets through faithful and transparent disclosures and for providing useful information to investors in a timely manner.
The company said it has continued to manage disclosure quality and strengthen internal processes to improve reliability while maintaining communication with investors, efforts it said contributed to greater market transparency.
Dongkook Pharmaceutical signs Korea distribution rights deal for Inhilo Plus skin booster
Dongkook Pharmaceutical said Thursday it signed a distribution rights agreement to expand domestic distribution of Inhilo Plus, a dual hyaluronic acid (HA)-based skin booster.
Inhilo is an injectable HA-based product approved as a Class 4 medical device categorized as a biomaterial for tissue repair. It is designed to provide immediate hydration through HA while stimulating fibroblasts to improve the skin’s structural environment via the extracellular matrix, the company said.
Dongkook said Inhilo’s dual-HA design combines low- and high-molecular-weight hyaluronic acid in one syringe (2 mL), which it said can support skin improvement effects.
Through the Korea rights agreement with BS Pharm Korea, Dongkook said it plans to secure a stable distribution network for Inhilo and strengthen its position in the domestic aesthetic medical market.
Inhilo is an injectable HA-based product approved as a Class 4 medical device categorized as a biomaterial for tissue repair. It is designed to provide immediate hydration through HA while stimulating fibroblasts to improve the skin’s structural environment via the extracellular matrix, the company said.
Dongkook said Inhilo’s dual-HA design combines low- and high-molecular-weight hyaluronic acid in one syringe (2 mL), which it said can support skin improvement effects.
Through the Korea rights agreement with BS Pharm Korea, Dongkook said it plans to secure a stable distribution network for Inhilo and strengthen its position in the domestic aesthetic medical market.
Kolon TissueGene presents knee osteoarthritis therapy at U.S. orthopedics meeting
Kolon TissueGene said Thursday that co-CEOs Jeon Seung-ho and Noh Moon-jong attended the 2026 American Academy of Orthopaedic Surgeons meeting, held March 2-6 local time in New Orleans, Louisiana.
The company described AAOS as the world’s largest orthopedics conference, drawing about 16,000 specialists and global biotech industry participants to share the latest research.
Kolon TissueGene said it presented existing clinical data and research progress for TG-C, which it is developing to treat knee osteoarthritis. The company said TG-C could offer an alternative for patients whose current options focus on pain relief or for whom total knee arthroplasty is the only fundamental treatment.
It also said it held discussions with potential partners on TG-C commercialization, including talks with medical affairs staff and advisory groups at global pharmaceutical companies on the therapy’s medical value and commercialization strategy.
The company described AAOS as the world’s largest orthopedics conference, drawing about 16,000 specialists and global biotech industry participants to share the latest research.
Kolon TissueGene said it presented existing clinical data and research progress for TG-C, which it is developing to treat knee osteoarthritis. The company said TG-C could offer an alternative for patients whose current options focus on pain relief or for whom total knee arthroplasty is the only fundamental treatment.
It also said it held discussions with potential partners on TG-C commercialization, including talks with medical affairs staff and advisory groups at global pharmaceutical companies on the therapy’s medical value and commercialization strategy.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.